Young-Sun Lin
Chief Scientific Officer Tripartite Therapeutics, Inc.
Dr. Young-Sun Lin is Founder and Chief Scientific Officer of Tripartite Therapeutics, where he leads the development of the company’s OmniLink® and Polarpeutic® technologies to address key challenges in ADC linker chemistry, payload delivery, and drug-to-antibody ratio optimization. A highly respected biotechnology leader, he previously served as CSO of Medigen, Founder and CSO of NovoTaiwan Biotechnology, and Deputy CEO and Director of R&D at Taiwan’s Development Center for Biotechnology. Dr. Lin earned his PhD in Biochemistry and Molecular Biology from Harvard University and is recognized for pioneering contributions to molecular biology, antibody therapeutics, and Taiwan’s biotechnology ecosystem.
Seminars
- Introducing OmniLink universal linker for rapid screening of optimal antibody-payload combinations with homogenous high DAR
- Showcasing OmniLink-constructed ADCs with different payloads, with exatecan and DM1 as illustrative examples versus current leading ADCs for the same payload classes
- Unveiling applications in novel ADC designs such as dual payload and immune-stimulating ADCs
